ZOLL MEDICAL CORP - FORM 10-Q

Attached files

Attached files

Stock widget

Investing forum

ZOLL MEDICAL CORP Reports

Also read

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

file	filename
EX-32.1 - CERTIFICATION OF CEO PURSUANT TO SECTION 906 - ZOLL MEDICAL CORP	dex321.htm
EX-32.2 - CERTIFICATION OF CFO PURSUANT TO SECTION 906 - ZOLL MEDICAL CORP	dex322.htm
EX-31.2 - CERTIFICATION OF CFO PURSUANT TO SECTION 302 - ZOLL MEDICAL CORP	dex312.htm
EX-31.1 - CERTIFICATION OF CEO PURSUANT TO SECTION 302 - ZOLL MEDICAL CORP	dex311.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended July 3, 2011.

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission File Number 0-20225

ZOLL MEDICAL CORPORATION

(Exact name of registrant as specified in its charter)


Massachusetts		04-2711626
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

269 Mill Road, Chelmsford, MA		01824-4105
(Address of principal executive offices)		(Zip Code)

(978) 421-9655

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data file required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ¨ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Indicate the number of shares outstanding of each of the issuer’s classes of Common Stock as of the latest practicable date:


Class		Outstanding at August 5, 2011
Common Stock, $0.01 par value		22,139,742

ZOLL MEDICAL CORPORATION

FORM 10-Q

INDEX


		Page No.
PART I. FINANCIAL INFORMATION

ITEM 1.	Financial Statements:

	Condensed Consolidated Balance Sheets (unaudited) July 3, 2011 and October 3, 2010		3

	Condensed Consolidated Statements of Income (unaudited) Three and Nine Months Ended July 3, 2011 and July 4, 2010		4

	Condensed Consolidated Statements of Cash Flows (unaudited) Nine Months Ended July 3, 2011 and July 4, 2010		5

	Notes to Condensed Consolidated Financial Statements (unaudited)		6

ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		16

ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk		27

ITEM 4.	Controls and Procedures		28

PART II. OTHER INFORMATION

ITEM 1.	Legal Proceedings		28

ITEM 1A.	Risk Factors		28

ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds		29

ITEM 5.	Other Information		29

ITEM 6.	Exhibits		29

Signatures			30

Forward-Looking Information

This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties. ZOLL Medical Corporation (the “Company,” “we,” “our,” or “us”) makes such forward-looking statements under the provisions of the “Safe Harbor” section of the Private Securities Litigation Reform Act of 1995. Actual future results may vary materially from those projected, anticipated, or indicated in any forward-looking statements as a result of certain known and unknown risk factors. Readers should pay particular attention to the risk factors described in Part I, Item 1A, “Risk Factors” of the Company’s Annual Report on Form 10-K for the fiscal year ended October 3, 2010 filed with the Securities and Exchange Commission (the “SEC”) on December 17, 2010 and Part II, Item 1A of this Quarterly Report on Form 10-Q. Readers should also carefully review the risk factors described in the other documents that we file from time to time with the SEC. In this report, the words “anticipates,” “believes,” “expects,” “intends,” “sees,” “future,” “may,” “will,” “could,” “would,” “estimates,” “plans,” and similar words or expressions (as well as other words or expressions referencing future events, conditions or circumstances) identify forward-looking statements. The Company assumes no obligation to update forward-looking statements or update the reasons why actual results, performances or achievements could differ materially from those provided in the forward-looking statements, except as required by law.

PART I. FINANCIAL INFORMATION

Item 1.

Financial Statements

ZOLL MEDICAL CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(000’s omitted, except per share data)

(Unaudited)


	July 3, 2011			Oct. 3, 2010
Assets
Current assets:
Cash and cash equivalents	$	59,468		$	59,058
Marketable securities		1,326			3,203
Accounts receivable, less allowances of $8,182 and $5,843 at July 3, 2011 and October 3, 2010, respectively		104,096			99,543
Inventories:
Raw materials		28,204			29,152
Work-in-process		9,322			6,799
Finished goods		28,264			34,007

		65,790			69,958
Prepaid expenses and other current assets		25,775			24,649

Total current assets		256,455			256,411

Property and equipment at cost:
Land, building and improvements		2,285			1,355
Machinery and equipment		86,481			79,388
Rental equipment		54,910			35,868
Construction in progress		1,814			3,180
Tooling		20,637			18,678
Furniture and fixtures		4,673			4,245
Leasehold improvements		7,218			6,533

		178,018			149,247
Less accumulated depreciation and amortization		112,283			99,324

Net property and equipment		65,735			49,923
Investments		1,310			1,310
Notes receivable		1,947			3,709
Goodwill		79,060			79,048
Intangibles and other assets, net		39,284			40,369

	$	443,791		$	430,770

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	20,441		$	22,801
Deferred revenue		21,676			20,871
Accrued expenses and other liabilities		31,224			54,526

Total current liabilities		73,341			98,198

Non-Current liabilities:
Other long-term liabilities		18,267			18,994

Total liabilities		91,608			117,192

Commitments and contingencies (Notes 8 and 14)
Stockholders’ equity:
Preferred stock, $0.01 par value, authorized 1,000 shares, none issued or outstanding		—			—
Common stock, $0.01 par value, authorized 38,000 shares, 22,060 and 21,504 issued and outstanding at July 3, 2011 and October 3, 2010, respectively		220			215
Capital in excess of par value		189,602			172,077
Accumulated other comprehensive loss		(5,229	)		(6,891	)
Retained earnings		167,590			148,177

Total stockholders’ equity		352,183			313,578

	$	443,791		$	430,770

See notes to unaudited condensed consolidated financial statements.

ZOLL MEDICAL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(000’s omitted, except per share data)

(Unaudited)


	Three Months Ended				Nine Months Ended
	July 3, 2011		July 4, 2010		July 3, 2011		July 4, 2010
Product sales	$	106,116	$	93,340	$	292,844	$	274,052
Rental revenue		30,035		17,986		78,964		49,544

Total revenue		136,151		111,326		371,808		323,596
Cost of products sold		50,032		46,760		141,096		136,697
Cost of rental revenue		6,974		4,483		18,854		11,945

Total cost of revenue		57,006		51,243		159,950		148,642

Gross profit		79,145		60,083		211,858		174,954
Expenses:
Selling and marketing		42,608		32,954		116,630		97,037
General and administrative		11,448		9,059		33,663		27,973
Research and development		11,676		11,570		33,613		34,225

Total expenses		65,732		53,583		183,906		159,235

Income from operations		13,413		6,500		27,952		15,719
Investment and other income (expense), net		222		122		939		348

Income before income taxes		13,635		6,622		28,891		16,067
Provision for income taxes		4,146		885		9,478		4,364

Net income	$	9,489	$	5,737	$	19,413	$	11,703

Basic earnings per common share	$	0.43	$	0.27	$	0.89	$	0.55

Weighted average common shares outstanding		21,963		21,445		21,765		21,343

Diluted earnings per common and common equivalent share	$	0.42	$	0.26	$	0.87	$	0.54

Weighted average common and common equivalent shares outstanding		22,703		21,859		22,350		21,675

See notes to unaudited condensed consolidated financial statements.

ZOLL MEDICAL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(000’s omitted)

(Unaudited)


	Nine Months Ended
	July 3, 2011			July 4, 2010
OPERATING ACTIVITIES:
Net income	$	19,413		$	11,703
Charges not affecting cash:
Depreciation and amortization		20,266			18,023
Stock-based compensation expense		3,180			3,080
Changes in current assets and liabilities:
Accounts receivable		(3,482	)		(835	)
Inventories		(16,317	)		(17,911	)
Prepaid expenses and other current assets		(1,082	)		(661	)
Accounts payable and accrued expenses		352			8,619

Cash provided by operating activities		22,330			22,018

INVESTING ACTIVITIES:
Sales of marketable securities		1,869			3,689
Additions to property and equipment		(11,398	)		(9,425	)
Payment of contingent consideration related to prior years’ acquisitions		(26,278	)		(12,798	)
Other assets, net		(1,095	)		(1,877	)

Cash used for investing activities		(36,902	)		(20,411	)

FINANCING ACTIVITIES:
Exercise of stock options		9,543			6,810
Stock option tax benefit		4,924			761
Taxes paid related to net share settlement of equity awards		(117	)		(64	)

Cash provided by financing activities		14,350			7,507

Effect of exchange rates on cash and cash equivalents		632			(1,059	)

Net increase in cash and cash equivalents		410			8,055
Cash and cash equivalents at beginning of period		59,058			51,061

Cash and cash equivalents at end of period	$	59,468		$	59,116

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid during the period:
Income taxes	$	2,159		$	4,164

See notes to unaudited condensed consolidated financial statements.

ZOLL MEDICAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting only of adjustments of a normal recurring nature) considered necessary for a fair presentation have been included. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Examples include provisions for returns, bad debts and the estimated lives of fixed assets. Actual results may differ from these estimates. The results for the interim periods are not necessarily indicative of results to be expected for the entire year. The information contained in the interim financial statements should be read in conjunction with the Company’s audited financial statements as of and for the year ended October 3, 2010 included in its Annual Report on Form 10-K filed with the SEC on December 17, 2010. Certain amounts in prior year financial statements have been reclassified to conform to current year presentation with no impact on net income or earnings per share.

The Company’s fiscal year ends on the Sunday closest to September 30. The current fiscal year will end on October 2, 2011 and will have 52 weeks while fiscal year 2010, which ended on October 3, 2010, included 53 weeks. The extra week was included in the Company’s first quarter of fiscal 2010.

2. Segment and Geographic Information

Segment information: The Company operates in a single business segment: the design, manufacture and marketing of technologies that help advance the practice of resuscitation and temperature control therapies for the treatment of critical care patients. In order to make operating and strategic decisions, the Company’s chief executive officer (the “chief operating decision maker”) evaluates revenue performance based on the worldwide revenues of four customer/product categories, but, due to shared infrastructures, profitability is based on an enterprise-wide measure. These customer/product categories consist of (1) the sale of resuscitation devices, temperature management products, accessories and disposable electrodes to the North American hospital market, including the military marketplace, (2) the sale of resuscitation devices, accessories, disposable electrodes and data collection management software to the North American pre-hospital market, (3) the sale of resuscitation devices, accessories, disposable electrodes, temperature management products and data collection management software to the International market, and (4) the rental of wearable resuscitation devices (LifeVest) in the North American and International pre-hospital markets.

Net sales by customer/product categories were as follows:


	Three Months Ended				Nine Months Ended
(000’s omitted)	July 3, 2011		July 4, 2010		July 3, 2011		July 4, 2010
Hospital Market—North America	$	35,352	$	29,735	$	96,432	$	89,883
Pre-hospital Market—North America		33,230		34,607		93,373		99,368
International Market-excluding North America		37,534		28,998		103,039		84,801
LifeVest-North America and International		30,035		17,986		78,964		49,544

	$	136,151	$	111,326	$	371,808	$	323,596

The Company reports assets on a consolidated basis to the chief operating decision maker.

Geographic information: Net sales by major geographical area, determined on the basis of destination of the goods, are as follows:


	Three Months Ended				Nine Months Ended
(000’s omitted)	July 3, 2011		July 4, 2010		July 3, 2011		July 4, 2010
United States	$	92,665	$	74,133	$	250,902	$	219,279
Foreign		43,486		37,193		120,906		104,317

	$	136,151	$	111,326	$	371,808	$	323,596

No individual foreign country represented 10% or more of the Company’s revenues or assets for the three or nine months ended July 3, 2011 or July 4, 2010. Therefore, no revenue attributable to any individual foreign country was material during these periods.

In each of the three or nine months ended July 3, 2011 or July 4, 2010, no single customer represented over 10% of the Company’s consolidated total revenue.

3. Comprehensive Income

The Company computes comprehensive income (loss) in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 220, Comprehensive Income, (formerly Statement of Financial Accounting Standard (SFAS) No. 130, Reporting Comprehensive Income). FASB ASC 220 establishes standards for the reporting and display of comprehensive income (loss) and its components in financial statements. Other comprehensive income (loss), as defined, includes all changes in equity during a period from non-owner sources, such as unrealized gains and losses on available-for-sale securities, unrealized gains and losses on derivative instruments and foreign currency translation. Total comprehensive income (loss) for the three and nine months ended July 3, 2011 or July 4, 2010, respectively, was as follows:


	Three Months Ended						Nine Months Ended
(000’s omitted)	July 3, 2011			July 4, 2010			July 3, 2011			July 4, 2010
Net income	$	9,489		$	5,737		$	19,413		$	11,703
Unrealized gain (loss) on available-for-sale securities		(9	)		113			(18	)		187
Unrealized gain (loss) on derivative instruments		39			—			(345	)		—
Foreign currency translation adjustment		588			(749	)		2,025			(747	)

Total comprehensive income	$	10,107		$	5,101		$	21,075		$	11,143

4. Stock Option Plans

At July 3, 2011, the Company had two active stock-based compensation plans under which stock-based grants may be issued, and two other stock-based compensation plans under which grants are no longer being made. No further grants are being made under the Company’s 1992 Stock Option Plan (“1992 Plan”) and 1996 Non-Employee Directors’ Stock Option Plan (“1996 Plan”), but option grants remain outstanding under both plans. The Company’s active plans are the Amended and Restated 2001 Stock Incentive Plan (“2001 Plan”) and the Amended and Restated 2006 Non-Employee Director Stock Option Plan (“2006 Plan”).

On November 16, 2010, the Board of Directors adopted certain amendments to the 2001 Plan and 2006 Plan. With respect to the 2001 Plan, the Board adopted, subject to stockholder approval, an amendment that increased by 920,000 shares (for a total of 4,170,000 shares) the shares of Common Stock available for issuance under the 2001 Plan. With respect to the 2006 Plan, the Board adopted, subject to stockholder approval, an amendment that increased by 35,000 shares (for a total of 192,500 shares) the shares of Common Stock available for issuance under the 2006 Plan. The amendments to both the 2001 Plan and the 2006 Plan were approved by the stockholders at the 2011 annual meeting held on February 10, 2011. The amendments to both Plans also generally prohibit a repricing through cancellation and re-grants or cancellation of stock options in exchange for cash.

Stock options outstanding under the 1992 Plan, the 1996 Plan, the 2001 Plan, and the 2006 Plan generally vest over a four-year period and have exercise prices equal to the fair market value of the Common Stock at the date of grant. All options have a 10-year contractual term. All options issued under the 2001 Plan and 2006 Plan must have an exercise price no less than fair market value on the date of grant. Restricted Common Stock grants made under the 2001 Plan will generally vest over a four-year period.

In accordance with FASB ASC 718, Compensation—Stock Compensation, the Company is required to measure the cost of employee services in exchange for an award of equity instruments based on the grant-date fair value of the award and to recognize cost over the requisite service period. The Company recognizes compensation expense on fixed awards with pro rata vesting on a straight-line basis over the vesting period.

Stock-based compensation charges totaled approximately $1.1 million and $3.2 million during the three and nine months ended July 3, 2011, respectively, and totaled approximately $1.3 million and $3.1 million during the three and nine months ended July 4, 2010, respectively. The effect of recording stock-based compensation by line item for the three and nine months ended July 3, 2011 and July 4, 2010 was as follows:


	Three Months Ended				Nine Months Ended
(000’s omitted)	July 3, 2011		July 4, 2010		July 3, 2011		July 4, 2010
Cost of revenue	$	106	$	52	$	293	$	207
Selling and marketing expense		199		302		604		680
General and administrative expense		657		738		1,954		1,720
Research and development expense		129		193		329		473

Total stock-based compensation	$	1,091	$	1,285	$	3,180	$	3,080

The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model with the following weighted average assumptions for grants issued during the nine months ended July 3, 2011 and July 4, 2010:


	Nine Months Ended July 3, 2011			Nine Months Ended July 4, 2010
Dividend yield		0	%		0	%
Expected volatility		44.1	%		42.4	%
Risk-free interest rate		1.59	%		2.37	%
Expected lives (years)		5.27			5.14

The weighted-average, grant-date fair value of options granted (estimated using the Black-Scholes option-pricing model) was $12.98 and $8.79 for the nine months ended July 3, 2011 and July 4, 2010, respectively. During the nine months ended July 3, 2011, the Company issued 544,617 shares of Common Stock pursuant to exercised options for proceeds of approximately $9.5 million. Total intrinsic value of options exercised for the nine months ended July 3, 2011 and July 4, 2010 was approximately $16.8 million and $2.7 million, respectively. It is the Company’s policy to issue new shares upon the exercise of options.

The following table summarizes the status of outstanding stock options as of July 3, 2011, as well as changes during the nine months ended July 3, 2011:


	Shares			Weighted- Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term in Years		Aggregate Intrinsic Value ($000’s)
Outstanding at October 3, 2010		2,084,011		$	19.35
Granted		414,000			31.46
Exercised		(544,617	)		17.52
Forfeited		(16,175	)		21.80

Outstanding at July 3, 2011		1,937,219		$	22.43		6.83	$	67,877

Exercisable at July 3, 2011		1,018,266		$	18.99		5.34	$	39,179

The following table summarizes the status of unvested restricted stock awards as of July 3, 2011, as well as changes during the nine months ended July 3, 2011:


	Shares			Weighted- Average Fair Value
Unvested at October 3, 2010		40,154		$	24.82
Granted		44,150			47.57
Vested		(14,208	)		24.95
Forfeited		(2,139	)		25.88

Unvested at July 3, 2011		67,957		$	39.54

At July 3, 2011, there was approximately $9.8 million of unrecognized compensation cost related to non-vested stock option and restricted stock awards, which the Company expects to recognize over a weighted-average period of 2.9 years.

5. Earnings per Share

The shares used for calculating basic earnings per share of Common Stock were the weighted average shares of Common Stock outstanding during the period, and the shares used for calculating diluted earnings per share of Common Stock were the weighted average shares of Common Stock outstanding during the period plus the dilutive effect of stock options and unvested restricted stock.


	Three Months Ended				Nine Months Ended
(000’s omitted)	July 3, 2011		July 4, 2010		July 3, 2011		July 4, 2010
Average shares outstanding for basic earnings per share		21,963		21,445		21,765		21,343
Dilutive effect of stock options and unvested restricted stock		740		414		585		332

Average shares outstanding for diluted earnings per share		22,703		21,859		22,350		21,675

Average shares outstanding for diluted earnings per share for the three and nine months ended July 3, 2011 does not include options to purchase 32,000 and 37,000 shares of Common Stock, respectively, as their effect would have been antidilutive. Average shares outstanding for diluted earnings per share for the three and nine months ended July 4, 2010 does not include options to purchase 219,000 and 950,000 shares of Common Stock, respectively, as their effect would have been antidilutive.

6. Derivative Instruments and Hedging Activities

The Company operates globally, and its earnings and cash flows are exposed to market risk from changes in currency exchange rates. The Company addresses these risks through a risk management program that includes the use of derivative financial instruments. The program is operated pursuant to documented corporate risk management policies. The Company does not enter into any derivative transactions for speculative purposes. The Company recognizes all derivative financial instruments in the condensed consolidated financial statements at fair value in accordance with FASB ASC 815, Derivatives and Hedging.

Designated Foreign Currency Contracts

The Company sometimes uses foreign currency forward contracts to manage its currency transaction exposures from forecasted foreign currency denominated sales to its subsidiaries. These foreign currency forward contracts are designated as cash flow hedges under FASB ASC 815, Derivatives and Hedging. Therefore, the effective portion of the gain or loss is reported as a component of other comprehensive income and will be reclassified into earnings in the same period or periods during which the hedged forecasted transaction affects earnings. The ineffective portion of the derivative’s change in fair value is recognized currently through earnings regardless of whether the instrument is designated as a hedge. At July 3, 2011, the Company had two foreign currency forward contracts designated as hedging instruments outstanding, all maturing in less than twelve months, to exchange the Euro for U.S. Dollars totaling approximately $5.4 million.

Net recognized losses from foreign currency forward contracts totaled approximately $223,000 and $369,000 during the three and nine months ended July 3, 2011 and are included in the condensed consolidated statements of income. The net settlement amount of the outstanding contracts recorded in “accumulated other comprehensive income” to recognize the effective portion of the fair value of the contracts at July 3, 2011 was an unrealized loss of approximately $345,000. The net settlement of these outstanding contracts will be reclassified to earnings within the next twelve months.

The following table presents the effect of the Company’s derivative instruments designated as hedging instruments on the condensed consolidated statements of income as of July 3, 2011 (in thousands):


Derivatives Designated as Hedging Instruments	Amount of Gain (Loss) Recognized in OCI (Effective Portion)			Amount of Gain (Loss) Reclassed from AOCI into Earnings (Effective Portion)			Location in Statement of Income	Amount of Gain (Loss) Recognized in Earnings on Ineffective Portion and Amount Excluded from Effectiveness Testing		Location in Statement of Income
Three months Ended July 3, 2011
Foreign currency contracts	$	39		$	(223	)	Investment and other income (expense), net	$	—

	$	39		$	(223	)		$	—


Derivatives Designated as Hedging Instruments	Amount of Gain (Loss) Recognized in OCI (Effective Portion)			Amount of Gain (Loss) Reclassed from AOCI into Earnings (Effective Portion)			Location in Statement of Income	Amount of Gain (Loss) Recognized in Earnings on Ineffective Portion and Amount Excluded from Effectiveness Testing		Location in Statement of Income
Nine Months Ended July 3, 2011
Foreign currency contracts	$	(345	)	$	(373	)	Investment and other income (expense), net	$	—

	$	(345	)	$	(373	)		$	—

The following table presents the fair value of the Company’s derivative instruments designated as a hedging instruments on the condensed consolidated balance sheet as of July 3, 2011 (in thousands):


Derivatives Designated as Hedging Instruments	Balance Sheet Location	Fair Value
Current liabilities
Foreign currency contracts	Accrued expenses and other liabilities	$	345

Total current liabilities		$	345

The Company did not enter into any derivative contracts designated as hedging instruments in the first nine months of fiscal 2010.

Non-Designated Foreign Currency Contracts

The Company also at times uses foreign currency forward contracts to manage its currency transaction exposures with intercompany receivables denominated in foreign currencies. These currency forward contracts are not designated as cash flow, fair value or net investment hedges under FASB ASC 815, Derivatives and Hedging, and therefore, are marked to market with changes in fair value recorded to earnings. These derivative instruments do not subject the Company’s earnings or cash flows to material risk since gains and losses on those derivatives generally offset losses and gains on the assets and liabilities being hedged.

The Company did not have any foreign currency forward contracts not designated as hedging instruments outstanding at July 3, 2011.

The Company had one foreign currency forward contract outstanding at October 3, 2010, serving to mitigate the foreign currency risk of a substantial portion of the Company’s Euro-denominated intercompany balances in the notional amount of approximately 5 million Euros. The fair value of this contract at October 3, 2010 was approximately $6.9 million, resulting in an unrealized loss of approximately $25,000 for the period ended October 3, 2010. We estimate the fair value of the derivative instruments based on the exchange rates of the underlying currencies.

The following table presents the fair value of the Company’s derivative instrument not designated as a hedging instrument as of October 3, 2010 (in thousands):


Derivatives Not Designated as Hedging Instruments	Balance Sheet Location	Fair Value
Current liabilities
Foreign currency contracts	Accrued expenses and other current liabilities	$	25

Total current assets		$	25

The following table presents the pretax impact that changes in the fair value of derivatives not designated as hedging instruments had on earnings during the three months ended July 3, 2011 and July 4, 2010, respectively:


(000’s omitted)	Location of Gain (Loss) Recognized in Income	Gain (Loss) Recognized in Income
(000’s omitted)	Location of Gain (Loss) Recognized in Income	Three Months Ended July 3, 2011		Three Months Ended July 4, 2010
Foreign currency contracts	Investment and other income (expense), net	$	125	$	517

The following table presents the pretax impact that changes in the fair value of derivatives not designated as hedging instruments had on earnings during the nine months ended July 3, 2011 and July 4, 2010, respectively:


(000’s omitted)	Location of Gain (Loss) Recognized in Income	Gain (Loss) Recognized in Income
(000’s omitted)	Location of Gain (Loss) Recognized in Income	Nine Months Ended July 3, 2011		Nine Months Ended July 4, 2010
Foreign currency contracts	Investment and other income (expense), net	$	90	$	1,147

7. Product Warranties

The Company typically offers one-year or five-year product warranties for most of its products. The Company provides for the estimated cost of product warranties at the time product revenue is recognized. Factors that affect the Company’s warranty reserves include the number of units sold, historical and anticipated rates of warranty repairs, and the cost per repair. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary.

Product warranty activity for the nine months ended July 3, 2011 and July 4, 2010 is as follows:


(000’s omitted)	Beginning Balance		Accruals for Warranties Issued During the Period		Decrease to Pre-existing Warranties		Ending Balance
Nine Months Ended July 3, 2011	$	4,304	$	1,392	$	1,248	$	4,448
Nine Months Ended July 4, 2010	$	4,176	$	1,372	$	1,355	$	4,193

8. Acquisitions

In October 2010, the Company acquired the assets and assumed certain liabilities of Road Safety International, Inc. (“Road Safety”). The Road Safety product is installed in an ambulance or fire vehicle and provides real-time feedback via audible alerts in situations such as speeding or hard cornering to help the driver avert an accident. The Road Safety product encourages a safer ambulance environment during patient treatment, records vehicle operating data for analysis, and can also be used to help reduce vehicle maintenance costs. The acquisition provides for consideration to be paid in the form of possible annual earn-out payments based on revenues for the next two fiscal years. If both earn-outs are achieved, total consideration (including liabilities assumed) could approximate $550,000. The contingent consideration is recorded in “accrued expenses and other liabilities” and “other long-term liabilities” on the Company’s condensed, consolidated balance sheet and no adjustments have been made to this accrual since it was originally recorded. Beginning October 4, 2010, the results of operations of Road Safety are included in the condensed, consolidated income statements of the Company. Proforma information is not provided as this acquisition was immaterial to the Company’s financial statements.

Contingent Consideration for Prior Period Acquisitions

The terms of the April 2006 acquisition of the assets of Lifecor, Inc. (“Lifecor”) provided for possible annual earn-out payments based upon revenue growth through fiscal 2010. The form of earn-out payments was at the discretion of the Company and could be made in the form of cash, Company stock, or a combination of the two. The earn-out payments for fiscal 2009 and 2010 were calculated as 100% of qualifying revenues earned in the current fiscal year in excess of the greater of the prior fiscal year qualifying revenues or $30 million. For fiscal 2010, approximately $26.3 million was accrued for payment to the former stockholders of Lifecor and was paid in the second quarter of fiscal 2011 in the form of cash. The fiscal 2010 earn-out payment was the final annual earn-out payment for the Lifecor acquisition. For fiscal 2009 and 2008, approximately $12.8 million and $4.5 million, respectively, was paid to Lifecor in the form of cash.

The terms of the March 2004 acquisition of the assets of Infusion Dynamics, Inc. (“Infusion Dynamics”) also provided for possible annual earn-out payments based upon revenue growth through fiscal 2011. Because additional consideration is based on the growth of sales, a reasonable estimate of the future payments to be made cannot be determined. Annual earn-out payments to former stockholders of Infusion Dynamics, in the form of cash, were approximately $19,000 for both fiscal 2009 and fiscal 2008. For fiscal 2010, approximately $25,000 was accrued at the end of fiscal 2010 for payment to the former shareholders of Infusion Dynamics and was paid in cash during the first quarter of fiscal 2011.

9. Inventory

The Company’s inventory is valued at the lower of cost or market. Cost is determined by the first-in, first-out (“FIFO”) method, including material, labor and factory overhead. Inventory on hand may exceed future demand either because the product is outdated or obsolete, or because the amount on hand is in excess of future needs. The total value of inventories that are determined to be obsolete based on criteria such as customer demand and changing technologies are reserved. Excess inventory amounts are estimated by reviewing quantities on hand and comparing those quantities to sales forecasts for the next 12 months, identifying historical service usage trends, and matching that usage with the installed base quantities to estimate future needs. At July 3, 2011, the Company’s inventory was recorded at net realizable value requiring reserves of $7.1 million, or 10% of the $72.9 million gross inventories. At October 3, 2010, the Company’s inventory was recorded at net realizable value requiring reserves of $7.1 million, or 9.2% of the $77.0 million gross inventories.

Because the LifeVest product is distributed on a rental basis, the LifeVest product is included in inventory while it is being manufactured, and once completed, it is then transferred to fixed assets and depreciated over its estimated life. During the three months ended July 3, 2011 and July 4, 2010, $7.2 million and $2.6 million, respectively, of LifeVest systems were transferred from inventory to fixed assets. As of July 3, 2011 and October 3, 2010, there was $9.1 million and $8.6 million of LifeVest related inventory, respectively. For purposes of the Company’s condensed, consolidated statement of cash flows, the transfer was treated as a non-cash transaction.

10. Goodwill, Intangibles and Other Assets

The changes in the carrying amount of goodwill for the nine months ended July 3, 2011 were as follows:


(000’s omitted)
Balance as of October 3, 2010	$	79,048
Goodwill acquired during the year		12

Balance as of July 3, 2011	$	79,060

The changes in the carrying amount of goodwill for the nine months ended July 4, 2010 were as follows:


(000’s omitted)
Balance as of September 27, 2009	$	52,100
Goodwill acquired during the year		671

Balance as of July 4, 2010	$	52,771

In accordance with ASC 350, Intangibles-Goodwill and Other, goodwill and intangible assets with indefinite lives are tested for impairment on an annual basis as of the end of the Company’s fiscal fourth quarter and between annual tests if indicators of potential impairment exist. No triggering events occurred or circumstances existed during the quarter ended July 3, 2011 to reassess these assets for impairment prior to the annual test.

Intangibles and other assets consist of:


			July 3, 2011				October 3, 2010
(000’s omitted)	Weighted Average Life		Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Prepaid license fees		16 years	$	12,872	$	5,105	$	12,764	$	4,495
Patents and developed technology		11 years		37,446		16,237		36,066		13,839
Customer-related intangibles		10 years		5,035		2,449		5,000		2,082
Intangible assets not subject to amortization		—		1,620		—		1,530		—
Other assets		—		11,166		5,064		9,512		4,087

			$	68,139	$	28,855	$	64,872	$	24,503

Amortization of intangibles for the three months ended July 3, 2011 and July 4, 2010 was approximately $1.5 million and $1.3 million, respectively, and is included in operating expenses in the consolidated statements of income. For the nine months ended July 3, 2011 and July 4, 2010, amortization of intangibles was approximately $4.3 million and $4.0 million, respectively, and is included in operating expenses in the consolidated statements of income.

11. Other Long-Term Liabilities

Other long-term liabilities consist of:


(000’s omitted)	July 3, 2011		October 3, 2010
Accrued warranty expense, long-term	$	2,755	$	2,789
Deferred revenue, long-term		6,194		7,597
Deferred tax liabilities		5,420		5,420
Unrecognized tax positions		3,188		3,188
Other miscellaneous liabilities		710		—

Total other long-term liabilities	$	18,267	$	18,994

12. Income Taxes

The effective tax rate for the three months ended July 3, 2011 and July 4, 2010 was 30% and 13%, respectively.

The Company’s effective tax rate for the nine months ended July 3, 2011 and July 4, 2010 was 33% and 27%, respectively. The Company’s current period tax rate was favorably impacted by discrete period return to accrual adjustments and expiration of tax statutes in the current period totaling approximately $1.5 million. The prior year’s rate was also impacted by the expiration of tax statutes and reductions of international tax liabilities also totaling approximately $1.5 million. However, due to the significant increase in profit before tax this year, the impact of these benefits in reducing the Company’s tax rate was less significant in the current period. The Company estimates that its fiscal 2011 effective tax rate will be approximately 35%.

As of July 3, 2011 and October 3, 2010, the Company had approximately $2.9 million and $3.8 million, respectively, of uncertain tax positions, of which $1.8 million and $2.2 million, respectively, if recognized, could impact the effective tax rate. No further reversals of uncertain tax positions are expected during fiscal 2011. The Company recognizes interest and penalties related to unrecognized tax benefits in income tax expense in the consolidated statements of income. The Company had $152,000 of accrued interest and penalties in income taxes payable as of July 3, 2011 and $312,000 as of October 3, 2010.

The Company is subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. The Company has concluded all U.S. federal and most state and foreign income tax matters through fiscal 2007. The Internal Revenue Service recently concluded an audit of our fiscal 2007 return with no material adjustments. The acquired losses from the business acquired from Revivant Corporation in fiscal 2005 for tax years 1997 through 2004 remain open to examination by the IRS to the extent losses are claimed in open years.

13. Fair Value Measurements

Effective September 29, 2008, the Fair Value Measurements and Disclosures topic, FASB ASC 820, formerly SFAS No. 157, “Fair Value Measurements,” required that financial assets and liabilities be re-measured and reported at fair value at each reporting period-end date, and that non-financial assets and liabilities are re-measured and reported at fair value at least annually (on a recurring basis). In the first quarter of fiscal 2010, the Company adopted FASB ASC 820 as it relates to any non-financial assets and non-financial liabilities that are recognized and disclosed at fair value in the financial statements on a nonrecurring basis. This adoption did not have a material impact on the Company’s financial results.

The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, the Company considers the principal or most advantageous market in which the Company would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions and credit risk.

The Company applies the following fair-value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

Level 1—Unadjusted quoted prices for identical assets or liabilities in an active market that the Company has the ability to access at the measurement date (examples include active exchange-traded equity securities, listed derivatives and most U.S. Government and agency securities).

Level 2—Quoted prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets. Level 2 inputs include the following:

•

Quoted prices for identical or similar assets or liabilities in non-active markets (examples include corporate and municipal bonds which trade infrequently);

•

Inputs other than quoted prices that are observable for substantially the full term of the asset or liability (examples include interest rate and currency swaps); and

•

Inputs that are derived principally from or corroborated by observable market data for substantially the full term of the asset or liability (examples include certain securities and derivatives).

Level 3—Prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset or liability. We currently do not have any Level 3 financial assets or liabilities.

The Company uses the market approach technique to value its assets and liabilities that are measured at fair value on a recurring basis. The Company’s financial assets and liabilities carried at fair value are primarily composed of marketable securities and derivative contracts used to hedge the Company’s currency risk. For Level 1 inputs, the Company used quoted market prices for financial instruments that have active markets. The financial instruments for which Level 1 inputs were used are money market funds and U.S. government agency and Treasury securities. For Level 2 inputs, the Company used quoted market prices in markets that are not active, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. The financial instruments for which Level 2 inputs are used were corporate obligations, all of which have counterparties with high credit ratings, and foreign currency contracts.

The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of July 3, 2011, and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value (in thousands):


(000’s omitted)	Total		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash equivalents	$	10,446	$	10,446	$	—	$	—
Available for sale securities (1)		1,326		—		1,326		—

Total	$	11,772	$	10,446	$	1,326	$	—


(000’s omitted)	Total		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Foreign currency contracts (2)	$	345	$	—	$	345	$	—

Total	$	345	$	—	$	345	$	—

(1)	Included in short-term marketable securities in the accompanying condensed consolidated balance sheet.

(2)	Included in accrued expenses and other liabilities in the accompanying condensed consolidated balance sheet.

The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of October 3, 2010, and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value (in thousands):


(000’s omitted)	Total		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash equivalents	$	13,575	$	13,575	$	—	$	—
Available for sale securities (1)		3,203		—		3,203		—

Total	$	16,778	$	13,575	$	3,203	$	—


(000’s omitted)	Total		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Foreign currency contracts (2)	$	25	$	—	$	25	$	—

Total	$	25	$	—	$	25	$	—

(1)	Included in short-term marketable securities in the accompanying condensed consolidated balance sheet.

(2)	Included in accrued expenses and other liabilities in the accompanying condensed consolidated balance sheet.

The Company held cost method investments of $1.3 million at July 3, 2011 and October 3, 2010. The fair value of a cost method investment is not estimated if there are no identified events or changes in circumstance that may have a significant adverse effect on the fair value of the investment. The Company has a policy in place to review its investments on a regular basis to evaluate the carrying value of the investments in these companies. If the Company believes that the carrying value of an investment is in excess of estimated fair value, it is the Company’s policy to record an impairment charge to adjust the carrying value to estimated fair value, if the impairment is deemed other-than-temporary.

14. Legal Proceedings

On June 18, 2010, Koninklijke Philips Electronics N.V. and Philips Electronics North America Corporation filed a lawsuit against the Company in U.S. District Court, Boston, MA, alleging infringement of fifteen patents owned by the Philips entities. The plaintiffs filed an amended complaint on October 13, 2010. On July 12, 2010, the Company filed a lawsuit against Philips Electronics North America Corporation in U.S. District Court, Boston, MA, alleging infringement of five patents owned by the Company.

The Company is, from time to time, involved in the normal course of its business in various legal proceedings, including intellectual property, contract, employment and product liability suits. Although the Company is unable to quantify the exact financial impact of any of these matters, it believes that none of the currently pending matters will have an outcome material to its financial condition or business.

15. Cash Equivalents and Marketable Securities

The Company considers all highly liquid instruments with an original maturity of three months or less to be cash equivalents. Substantially all cash and cash equivalents are invested in U.S. Treasury Bills and other U.S. government agency securities. The Company accounts for marketable securities in accordance with FASB ASC 320, Investments—Debt and Equity Securities. All marketable securities must be classified as one of the following: held-to-maturity, available-for-sale, or trading. The Company classifies its marketable securities as available-for-sale and, as such, carries the investments at fair value, with unrealized holding gains and losses reported in stockholders’ equity as a separate component of accumulated other comprehensive income (loss). The cost of securities sold is determined based on the specific identification method. Realized gains and losses, and declines in value judged to be other than temporary, are included in investment income.

As of July 3, 2011, available-for-sale securities consisted of the following:

		0000		0000		0000		0000			0000
(000’s omitted)	Cost		Accrued Interest		Gross Unrealized					Estimated Fair Value
(000’s omitted)	Cost		Accrued Interest		Gains		Losses			Estimated Fair Value
Money-market funds	$	98	$	—	$	—	$	—		$	98
U.S. government agency and Treasury securities		10,308		42		—		(2	)		10,348
Corporate obligations		1,304		9		13		—			1,326

	$	11,710	$	51	$	13	$	(2	)	$	11,772

As of October 3, 2010, available-for-sale securities consisted of the following:


(000’s omitted)	Cost		Accrued Interest		Gross Unrealized				Estimated Fair Value
(000’s omitted)	Cost		Accrued Interest		Gains		Losses		Estimated Fair Value
Money-market funds	$	77	$	—	$	—	$	—	$	77
U.S. government agency and Treasury securities		13,498		—		—		—		13,498
Corporate obligations		3,163		10		30		—		3,203

	$	16,738	$	10	$	30	$	—	$	16,778

The contractual maturities of these investments as of July 3, 2011 were as follows:

		00000		00000
(000’s omitted)	Cost		Fair Value
Within 1 year	$	11,710	$	11,772
After 1 year through 5 years		—		—
After 5 years through 10 years		—		—
After 10 years		—		—

	$	11,710	$	11,772

The contractual maturities of these investments as of October 3, 2010 were as follows:


(000’s omitted)	Cost		Fair Value
Within 1 year	$	13,575	$	13,575
After 1 year through 5 years		3,160		3,200
After 5 years through 10 years		—		—
After 10 years		3		3

	$	16,738	$	16,778

The Company’s available-for-sale securities were included in the following captions in the condensed consolidated balance sheets:


(000’s omitted)	July 3, 2011		October 3, 2010
Cash equivalents	$	10,446	$	13,575
Marketable securities		1,326		3,203

	$	11,772	$	16,778

Gross realized gains and (losses) on available-for-sale securities for the three and nine months ended July 3, 2011 and July 4, 2010, included in “Investment and other income, net” on the consolidated income statements, were as follows:


(000’s omitted)	For Three Months Ended July 3, 2011		For Three Months Ended July 4, 2010		For Nine Months Ended July 3, 2011		For Nine Months Ended July 4, 2010
Gross realized gains	$	—	$	1	$	—	$	1
Gross realized losses		—		—		—		—

Total, net	$	—	$	1	$	—	$	1

16. Recent Accounting Pronouncements

Recently Adopted Accounting Pronouncements:

Effective January 4, 2010, the Company adopted ASU No. 2010-06, Fair Value Measurements and Disclosures (Topic 820)—Improving Disclosures about Fair Value Measurements (ASU 2010-06). ASU 2010-06 requires additional disclosure within the roll-forward activity for assets and liabilities measured at fair value on a recurring basis, including transfers of assets and liabilities between Level 1 and Level 2 of the fair value hierarchy and the separate presentation of purchases, sales, issuances and settlements of assets and liabilities within Level 3 of the fair value hierarchy. In addition, ASU 2010-06 requires enhanced disclosures of the valuation techniques and inputs used in the fair value measurements within Level 2 and Level 3. ASU 2010-06 was adopted beginning

with the Company’s second quarter ended April 4, 2010, except for the disclosure of purchases, sales, issuances and settlements of Level 3 measurements, for which disclosures were not required until the Company’s first quarter of fiscal 2011. The Company did not have any transfers of assets or liabilities between Level 1 and Level 2 of the fair value hierarchy during fiscal 2010 and fiscal 2011 to date. See Note 13. The adoption of the additional disclosures for Level 1 and Level 2 fair value measurements did not have a material impact on the Company’s financial position, results of operations or cash flows. The Company adopted the requirement of additional disclosures of purchases, sales, issuances and settlements of Level 3 measurements beginning with the Company’s quarter ended January 2, 2011. The adoption of the additional requirements had no impact on the Company’s financial position, results of operations or cash flows.

In December 2010, the FASB issued ASC update No. 2010-28, Intangibles-Goodwill and Other (Topic 350), When to Perform Step 2 of the Goodwill Impairment Test for Reporting Units with Zero or Negative Carrying Amounts a consensus of the FASB Emerging Issues Task Force (ASC 2010-28). This amendment modifies Step 1 of the goodwill impairment test for reporting units with zero or negative carrying amounts. For those reporting units, an entity is required to perform Step 2 of the goodwill impairment test if it is more likely than not that a goodwill impairment exists. The qualitative factors that an entity should consider when evaluating whether it is more likely than not that a goodwill impairment exists are consistent with the existing guidance for determining whether an impairment exists between annual tests. The adoption of this update did not have a material impact on the Company’s financial statements. This update was effective for fiscal periods beginning after December 15, 2010.

In December 2010, the FASB issued ASC update No. 2010-29, Business Combinations (Topic 805), Disclosure of Supplementary Pro forma Information for Business Combinations a consensus of the FASB Emerging Issues Task Force (ASC 2010-29). This amendment clarifies the periods for which pro forma financial information is presented. The disclosures include pro forma revenue and earnings of the combined entity for the current reporting period as though the acquisition date for all business combinations that occurred during the year had been as of the beginning of the annual reporting period. If comparative financial statements are presented, the pro forma revenue and earnings of the combined entity for the comparable prior reporting period should be reported as though the acquisition date for all business combinations that occurred during the current year had been as of the beginning of the comparable prior annual reporting period. The adoption of this update did not have a material impact on the Company’s financial statements. This update was effective for fiscal periods beginning after December 15, 2010.

Recently Issued Accounting Pronouncements:

In June 2011, the FASB issued ASC update No. 2011-05, Comprehensive Income (Topic 220): Presentation of Comprehensive Income, (ASC 2011-05). The amendments in this ASC require an entity to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. ASC 2011-05 eliminates the option to present the components of other comprehensive income as part of the statement of equity. ASC 2011-05 is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2011, with early adoption permitted. The Company is currently evaluating the impact of adopting ASC 2011-05 on its consolidated financial statements.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

We are committed to developing technologies that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, we provide a comprehensive set of technologies which help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.

We intend for this discussion and analysis to provide you with information that will assist you in understanding our consolidated financial statements. Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States. This discussion and analysis should be read in conjunction with our consolidated financial statements as of July 3, 2011 and for the three and nine months then ended and the notes thereto.

Our fiscal 2011 consists of 52 weeks while our fiscal 2010 consisted of 53 weeks. Therefore, while the nine months ended July 3, 2011 consisted of 39 weeks, the nine months ended July 4, 2010 included the additional week and consisted of 40 weeks. We estimate that the revenue and expense impact of the additional week was approximately $2 million each during the three months ended January 3, 2010.

Our sales for the three months ended July 3, 2011 increased 22% to $136.2 million, as compared to the same period in the prior year. The increase in sales was driven primarily by the LifeVest and International businesses. LifeVest revenue grew 67% in the three months ended July 3, 2011 compared to the same period in fiscal 2010 as this product continues to gain greater acceptance and we expand the LifeVest sales force both in the U.S. and Germany. International revenues grew 29% in the three months ended July 3, 2011 compared to the same period in the prior fiscal year. This increase in International revenues is related primarily to higher sales volume of our defibrillator products and, to a lesser extent, our Temperature Management and AutoPulse products. Revenues from the North American hospital core defibrillator business, excluding military, grew modestly in the three months ended July 3, 2011 compared to revenues from this business in the prior-year quarter. The North American EMS environment continues to experience funding restrictions within public agencies, and revenue was down from the prior-year quarter. Although, on a shipments basis, North American EMS was down and North American hospital core defibrillator business only grew modestly, orders in both these markets were up over 25% which is reflected in our increased backlog. Our gross margin reflected favorable North American pricing, an increased volume of higher margin LifeVest business and favorable International business mix.

Three Months Ended July 3, 2011 Compared To Three Months Ended July 4, 2010

Sales

Net sales by customer/product categories are as follows:


(000’s omitted)	July 3, 2011		July 4, 2010		% Change
Devices and Accessories to the Hospital Market-North America	$	35,352	$	29,735		19	%
Devices, Accessories, and Data Management Software to the Pre-hospital Market-North America		33,230		34,607		(4	%)
Devices, Accessories, and Data Management Software to the International Market		37,534		28,998		29	%
LifeVest to the North America and International Markets		30,035		17,986		67	%

Net Sales	$	136,151	$	111,326		22	%

Our sales to the North American hospital market increased approximately 19% to $35.4 million, compared to the same period a year ago. The increase was primarily due to increased volume of US Military/Big Government sales and sales of our professional defibrillators.

Our sales to the North American pre-hospital market decreased approximately $1.4 million, or 4%, during the three months ended July 3, 2011, compared to the same quarter in the prior year. The decrease in North American pre-hospital market sales was the result of a decreased volume in professional defibrillators. Although shipments were down compared to the prior year period, we did see solid order growth. We believe this is a positive sign, although we believe spending may remain constrained for the next few quarters due to concerns surrounding the general economic environment.

International sales increased approximately $8.5 million, or 29%, during the three months ended July 3, 2011, in comparison to the prior-year period. The increase was primarily driven by increased sales volume of defibrillators and revenue derived from our Temperature Management business. The increased volume of sales was driven primarily by our direct subsidiaries in Australia and the United Kingdom and our international distributors in Europe. Sales by these direct subsidiaries also included a positive impact from foreign currency exchange rate fluctuations, excluding Canada, of approximately $2 million.

Total rental revenue of the LifeVest product increased 67% to $30.0 million in the third quarter of fiscal 2011 compared to $18.0 million in the same period of the prior year. This increase is the result of increased acceptance of the LifeVest product, improved productivity of our existing sales force and an increase in sales personnel both in the U.S. and in Germany.

Total sales of our Temperature Management products to all of our markets increased $2.0 million, or 40%, from $5.0 million in the third quarter of fiscal 2010 to $7.0 million in the third quarter of fiscal 2011. This growth is primarily attributable to increased sales in the International market.

Total sales of the AutoPulse product to all of our markets increased 31% during the three months ended July 3, 2011, compared to the three months ended July 4, 2010. Total AutoPulse sales were approximately $5.0 million in the third quarter of fiscal 2011 in comparison to $3.8 million in the prior-year quarter.

Gross Margins

Cost of sales consists primarily of material, direct labor, overhead, and freight associated with the manufacturing of our various medical equipment devices, data collection software and disposables. These products are primarily sold to the hospital, pre-hospital and International markets. We lease the LifeVest product and sell our data collection software mainly to the pre-hospital market.

Gross margin for the three months ended July 3, 2011 increased to 58%, as compared with 54% during the same period in the prior year. This increase primarily reflected favorable North American pricing, an increased volume of higher margin LifeVest business and favorable International business mix. Other factors, including foreign exchange rate fluctuations, affecting the change in gross margin each individually represented less than one percentage point of our overall gross margin. Our gross margin tends to fluctuate from period to period as a result of unit volume levels, mix of product and customer class, geographical mix, foreign exchange rate fluctuations and overall market conditions.

Backlog

Backlog increased to approximately $32 million at July 3, 2011, compared to approximately $29 million at the end of the prior quarter. Backlog was approximately $14 million at July 4, 2010. Typically, we expect our backlog to decrease sequentially during the first and second quarters, remain flat during the third quarter, and increase during the fourth quarter due to the purchasing practices of our customers. We believe the maintenance of a modest backlog will help improve our efficiency, lower our costs and improve our profitability as we believe it will make it less likely that we will be required to incur substantial additional costs at the end of the quarter. Due to possible changes in delivery schedules, cancellation of orders and delays in shipments, our backlog at any particular date is not necessarily an accurate predictor of revenue for any succeeding period.

Costs and Expenses

Operating expenses for the three months ended July 3, 2011 and July 4, 2010 were as follows:


(000’s omitted)	July 3, 2011		% of Sales			July 4, 2010		% of Sales			Change %
Selling and marketing	$	42,608		31	%	$	32,954		30	%		29	%
General and administrative		11,448		8	%		9,059		8	%		26	%
Research and development		11,676		9	%		11,570		10	%		1	%

Total expenses	$	65,732		48	%	$	53,583		48	%		23	%

As a percentage of sales, selling and marketing expenses for the three months ended July 3, 2011 increased one percentage point to 31% compared to 30% for the three months ended July 4, 2010. The increased dollar spending for the three months ended July 3, 2011, compared to the three months ended July 4, 2010, primarily reflected increased expenses for the LifeVest sales force compensation and other costs related to the growth of this business, and, to a lesser extent, our core International and North American capital equipment sales force costs.

As a percentage of sales, general and administrative expenses remained flat at 8% of sales during the three months ended July 3, 2011, compared to the three months ended July 4, 2010. The increased dollar spending during the three months ended July 3, 2011 primarily reflected increased salaries and fringe benefits, particularly in support of the LifeVest business.

As a percentage of sales, research and development expenses for the three months ended July 3, 2011 decreased approximately one percentage point to 9% compared to 10% for the three months ended July 4, 2010. Research and development expenses decreased for the three months ended July 3, 2011 compared to the three months ended July 4, 2010, primarily due to reduced spending for clinical trials as patient enrollment in our AutoPulse clinical trial ended in January 2011. The decrease was partially offset by increased personnel-related expenses.

Investment and Other Income (Expense), Net

Investment and other income (expense), net includes interest income, realized and unrealized foreign exchange gains and losses, and other income and expense. Investment and other income (expense), net totaled approximately $222,000 and $122,000 for the three months ended July 3, 2011 and July 4, 2010, respectively. This improvement is primarily the result of the weaker US dollar during the third quarter of 2011 as we marked our foreign denominated intercompany receivables to market at the end of the quarter.

Income Taxes

Our effective tax rate for the three months ended July 3, 2011 and July 4, 2010 was 30% and 13%, respectively. The difference between the effective rates is primarily due to the impact of discrete period items on both three-month periods. However, due to the significant increase on earnings before tax for 2011, the impact of these benefits on our tax rate was less significant than in the prior year period.

As of July 3, 2011 and October 3, 2010, we had approximately $2.9 million and $3.8 million, respectively, of uncertain tax positions, of which $1.8 million and $2.2 million, respectively, if recognized, could impact the effective tax rate. No further reversals of uncertain tax positions are expected in fiscal 2011. We recognize interest and penalties related to unrecognized tax benefits in income tax expense in the consolidated statements of income. We had $152,000 of accrued interest and penalties in income taxes payable as of July 3, 2011 and $312,000 as of October 3, 2010.

We are subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. We have concluded all U.S. federal and most state and foreign income tax matters through fiscal 2007. The Internal Revenue Service recently concluded an audit of our fiscal 2007 return with no material adjustments. The acquired losses from the business acquired from Revivant Corporation in fiscal 2005 for tax years 1997 through 2004 remain open to examination by the IRS to the extent losses are claimed in open years.

Nine Months Ended July 3, 2011 Compared To Nine Months Ended July 4, 2010

Sales

Net sales by customer/product categories are as follows:


(000’s omitted)	July 3, 2011		July 4, 2010		% Change
Devices and Accessories to the Hospital Market-North America	$	96,432	$	89,883		7	%
Devices, Accessories, and Data Management Software to the Pre-hospital Market-North America		93,373		99,368		(6	%)
Devices, Accessories, and Data Management Software to the International Market		103,039		84,801		22	%
LifeVest to the North America and International Markets		78,964		49,544		59	%

Net Sales	$	371,808	$	323,596		15	%

Net sales increased approximately 15% for the nine months ended July 3, 2011 compared to the prior-year period.

Sales to the North American hospital market increased approximately 7% compared to the same period a year ago. This increase was attributable primarily to an increase in volume of US Military/Big Government sales and, to a lesser extent, increased sales of our defibrillator and Temperature Management products sold to hospitals.

Sales to the North American pre-hospital market decreased approximately $6.0 million, or 6%, compared to the same period in the prior year. The decrease in North American pre-hospital market sales was the result of a decreased volume in professional defibrillator sales and, to a lesser extent, decreased sales volume of our AEDs. We believe the decreased revenue is a result of spending constraints in the pre-hospital market in the general economic environment, and we expect that these constraints will continue throughout the remainder of the fiscal year.

International sales increased approximately $18.2 million, or 22%, during the nine months ended July 3, 2011, in comparison to the prior-year period. The increase was primarily due to increased volume of defibrillator sales and Temperature Management product sales. The increased volume of sales was driven by our direct subsidiaries in Australia and the United Kingdom and our international distributors in China and the Middle East. Sales by our international subsidiaries were positively impacted by foreign currency exchange rate fluctuations of approximately $2.4 million.

Total rental revenue of the LifeVest product increased 59% to $79.0 million in the first nine months of fiscal 2011 compared to $49.5 million in the same period of the prior year. Adjusting for the extra week in the prior year, LifeVest revenues increased 63%. This increase is the result of increased acceptance of the LifeVest product, improved productivity of our existing sales force and an increase in sales personnel both in the U.S. and Germany.

Total sales of our Temperature Management products to all of our markets increased $5.3 million, or 39%, from $13.6 million in the first nine months of fiscal 2010 to $18.9 million in the first nine months of fiscal 2011. This growth is primarily attributable to an increased volume of sales in the International market.

Total sales of the AutoPulse product to all of our markets increased 5% during the nine months ended July 3, 2011, compared to the nine months ended July 4, 2010. Total AutoPulse sales were approximately $12.9 million in comparison to $12.2 million in the prior-year period.

Gross Margins

Gross margin for the nine months ended July 3, 2011 increased from 54% to 57% compared to the same period in the prior year. The gross margin increased primarily due to the increased volume of higher margin LifeVest business. Other factors, including changes in pricing and international business mix, affecting the fluctuation in gross margin each individually represented less than one percentage point of our overall gross margin. Our gross margin tends to fluctuate from period to period as a result of unit volume levels, mix of product and customer class, geographical mix, foreign exchange rate fluctuations and overall market conditions.

Costs and Expenses

Operating expenses for the nine months ended July 3, 2011 and July 4, 2010 were as follows:


(000’s omitted)	Nine Months Ended July 3, 2011		% of Sales			Nine Months Ended July 4, 2010		% of Sales			Change %
Selling and marketing	$	116,630		31	%	$	97,037		30	%		20	%
General and administrative		33,663		9	%		27,973		9	%		20	%
Research and development		33,613		9	%		34,225		10	%		(2	%)

Total expenses	$	183,906		49	%	$	159,235		49	%		15	%

As a percentage of sales, selling and marketing expenses for the nine months ended July 3, 2011 increased one percentage point to 31% compared to 30% for the nine months ended July 4, 2010. The increased dollar spending primarily reflected increased expenses for the LifeVest sales force compensation and other costs related to the growth of this business. The increase is also attributable to increased costs related to the International business sales force as this business continues to expand.

As a percentage of sales, general and administrative expenses remained flat at 9% of sales for the nine months ended July 3, 2011 and July 4, 2010. The increased dollar spending for general and administrative expenses primarily reflected increased salaries and fringe benefits, including in support of the LifeVest business.

As a percentage of sales, research and development expenses for the nine months ended July 3, 2011 decreased approximately one percentage point compared to the nine months ended July 4, 2010. Research and development expenses decreased for the nine months ended July 3, 2011 compared to the nine months ended July 4, 2010, due predominantly to decreased costs related to our clinical trials. These decreases were partially offset by increased personnel-related expenses, including salaries and fringe benefits.

Investment and Other Income (Expense), Net

Investment and other income (expense), net includes interest income, realized and unrealized foreign exchange gains and losses, and other income and expense. Investment and other income (expense), net totaled approximately $939,000 and $348,000 for the nine months ended July 3, 2011 and July 4, 2010, respectively. This increase is primarily the result of the weakening U.S. dollar during fiscal 2011, as compared to fiscal 2010, as we marked our short-term foreign denominated intercompany receivables to market at the end of the reporting period.

Income Taxes

Our effective tax rate for the nine months ended July 3, 2011 and July 4, 2010 was 33% and 27%, respectively. The difference between the effective rates is primarily due to the impact of discrete period items of approximately $1.5 million on both nine-month periods. However, due to the significant increase on earnings before tax for fiscal 2011, the impact of these benefits on our tax rate was less significant than in the prior year period. The current period rate also was affected by an increase in the state income tax provision for fiscal 2011. We estimate that our fiscal 2011 effective tax rate will be approximately 35%.

Liquidity and Capital Resources

We believe that our overall financial condition remains strong. Our cash, cash equivalents and short-term marketable securities at July 3, 2011 totaled $60.8 million compared with $62.3 million at October 3, 2010. We continue to have no long-term debt. During the second quarter of fiscal 2011, we paid approximately $26.3 million in cash to the former stockholders of Lifecor for the fiscal 2010 earn-out, which was the final earn-out for this acquisition.

As we have previously stated, we have used cash, and it is possible we will use additional cash, to assist customers who transition to our products with various financing arrangements. We also may use cash to assist creditworthy customers with various financing arrangements as a result of the current difficult liquidity and credit environment.

Cash Requirements

We believe that the combination of existing cash, cash equivalents, and highly liquid short-term investments, together with future cash to be generated by operations and amounts available under our unsecured line of credit of up to $12 million, will be sufficient to meet our ongoing operating and capital expenditure requirements for the foreseeable future. We believe we have, and will maintain, sufficient cash to meet future contingency payments related to acquisitions made in prior periods.

We may also need to use these funds in the future for potential acquisitions.

Sources and Uses of Cash

To assist with the discussion, the following table presents the abbreviated cash flows for the nine months ended July 3, 2011 and July 4, 2010:


(000’s omitted)	Nine months ended July 3, 2011			Nine months ended July 4, 2010
Net income	$	19,413		$	11,703
Changes not affecting cash		23,446			21,103
Changes in current assets and liabilities		(20,529	)		(10,788	)

Cash provided by operating activities		22,330			22,018
Cash used for investing activities		(36,902	)		(20,411	)
Cash provided by financing activities		14,350			7,507
Effect of foreign exchange rates on cash		632			(1,059	)

Net change in cash and cash equivalents		410			8,055
Cash and cash equivalents - beginning of period		59,058			51,061

Cash and cash equivalents - end of period	$	59,468		$	59,116

Operating Activities

Cash provided by operating activities of $22.3 million for the nine months ended July 3, 2011 was flat compared to cash provided by operating activities for the nine months ended July 4, 2010 of $22.0 million. The slight increase in cash provided by operating activities for the nine months ended July 3, 2011, as compared to the nine months ended July 4, 2010, was primarily attributable to higher net income and less cash used for prepaid expenses and other current assets for the nine months. These increases were almost offset by a decrease in cash provided by accounts payable and accrued expenses and, to a lesser extent, less cash provided by accounts receivable.

Investing Activities

Cash used in investing activities during nine months ended July 3, 2011 increased by approximately $16.5 million compared to cash used in investing activities during the nine months ended July 4, 2010. This increase is primarily attributable to more cash paid out in fiscal year 2011 as contingent consideration for prior-year acquisitions than in the previous fiscal year. This increase also was the result of more additions to fixed assets and less cash having been generated from sales of marketable securities during the nine months ended July 3, 2011 as compared to the same period in the prior year. These increases were partially offset by fewer additions to other assets during the nine months ended July 3, 2011 compared to the nine months ended July 4, 2010.

Financing Activities

Cash provided by financing activities during the nine months ended July 3, 2011 increased approximately $6.8 million compared to the nine months ended July 4, 2010. The change reflects a higher number of stock options exercised during the first nine months of fiscal 2011 than in the comparable period of fiscal 2010. (Options for 544,617 shares were exercised in the current period compared to options for 370,442 shares exercised in the previous year period.) The increase also was attributable to a greater tax benefit received from stock options exercised in fiscal 2011 period than in the fiscal 2010 period.

Investments

In March 2004, we acquired substantially all the assets of Infusion Dynamics. Under the terms of the acquisition, we are obligated to make additional earn-out payments through 2011 (“contingencies”) based on the performance of the acquired business (See Note 8). Because additional consideration is based on the growth of sales, a reasonable estimate of the future payments to be made cannot be determined. As these contingencies are resolved and the consideration is distributable, we record the fair value of the additional consideration as additional cost of the acquired assets. Our earn-out payments, in the form of cash, for fiscal 2010, 2009 and 2008 were approximately $25,000, $19,000 and $19,000, respectively. The annual earn-outs were accrued during the fiscal period when earned and paid out in the subsequent fiscal period.

We exercised our option to acquire the business and assets of Lifecor, Inc. on March 22, 2006 and acquired the business and assets on April 10, 2006. We assumed Lifecor’s outstanding debt (plus an additional $3.0 million owed to us, which was cancelled) and certain stated liabilities. We paid the third-party debt in April 2006. We agreed to pay additional consideration in the form of earn-out payments to Lifecor based upon future revenue growth of the acquired business over a five-year period (See Note 8). The earn-out payment to Lifecor for fiscal 2009 and fiscal 2008 were both made in the form of cash in the approximate amounts of $12.8 million and $4.5 million, respectively. In the fourth quarter of fiscal 2010, we accrued approximately $26.3 million for the fiscal 2010 earn-out which was paid in cash to Lifecor in the second quarter of fiscal 2011. The annual earn-outs were accrued during the fiscal period when earned and paid out in subsequent fiscal periods. The fiscal 2010 payment was the final earn-out payment for the Lifecor acquisition. The total earnout payments for this acquisition were $46.8 million, and all payments were made in cash.

In October 2010, we acquired the assets and assumed certain liabilities of Road Safety International, Inc. (“Road Safety”). The Road Safety product is installed in an ambulance or fire vehicle and provides real-time feedback via audible alerts in situations such as speeding or hard cornering to help the driver avert an accident. The Road Safety product encourages a safer ambulance environment during patient treatment, records vehicle operating data for analysis, and can also be used to help reduce vehicle maintenance costs. The acquisition provides for consideration to be paid in the form of possible annual earn-out payments based on revenues for the next two fiscal years. If both earn-outs are achieved, total consideration (including liabilities assumed) could approximate $550,000.

Debt Instruments and Related Covenants

We maintain an unsecured working capital line of credit with our bank. Under this working capital line, we may borrow, on a demand basis, up to $12 million. This line of credit bears interest at the rate of LIBOR plus 2%. No borrowings were outstanding on this line during fiscal 2010 or fiscal 2011 to date. There are no covenants related to this line of credit.

Off-Balance Sheet Arrangements

Our only off-balance sheet arrangements consist of non-cancelable operating leases entered into in the ordinary course of business and one minimum purchase commitment contract for critical raw material components. The table shown below in the next section titled “Contractual Obligations and Other Commercial Commitments” shows the amounts of our operating lease commitments and purchase commitments payable by year. For liquidity purposes, we generally choose to lease our facilities instead of purchasing them.

Contractual Obligations and Other Commercial Commitments

The following table sets forth certain information concerning our obligations and commitments to make future payments under contracts, such as lease agreements.


	Payments Due by Period
(000’s omitted)	Total		Less than 1 Year		1-3 Years		4-5 Years		After 5 Years
Contractual Obligations
Non-Cancelable Operating Lease Obligations	$	39,398	$	2,789	$	8,909	$	9,164	$	18,536
Purchase Obligations		647		647		—		—		—

Total Contractual Obligations	$	40,045	$	3,436	$	8,909	$	9,164	$	18,536

We lease certain office and manufacturing space under operating leases. Our office leases are subject to adjustments based on actual floor space occupied. The leases also require payment of real estate taxes and operating costs. In addition to the office leases, we lease automobiles for business use by a portion of the sales force.

Our executive headquarters and defibrillator and fluid resuscitation manufacturing operations are located in Chelmsford, Massachusetts. The Chelmsford facility was covered by an eight-year lease, beginning July 1, 2003 and which expired on June 29, 2011, as well as two smaller subleases that also expired on June 29, 2011. The agreements provided that we pay a pro-rata amount of the landlord’s real estate tax and operating expenses based upon square footage. The main lease also provided us with an allowance of approximately $3.7 million for any construction costs associated with our relocation efforts to this leased facility. This reimbursement has been recorded as a deferred lease incentive within accrued expenses and other liabilities and is being amortized as a reduction to rent expense over the life of the lease. Any leasehold improvements made as part of the relocation have been capitalized as leasehold improvements within “Property and Equipment” and are being amortized over the eight year life of the lease. We entered into a new 10-year lease for our Chelmsford facility on December 29, 2010 which commenced on June 30, 2011 and expires on June 30, 2021. The new lease agreement includes an option to renew the lease for two successive periods of five years each. We will continue to pay a pro-rata amount of the landlord’s real estate tax and operating expenses based upon square footage.

Purchase obligations include all legally binding contracts that are non-cancelable. Purchase orders or contracts for the purchase of raw materials and other goods and services are not included in the table above. Purchase orders represent authorizations to purchase rather than binding agreements. For the purposes of the table above, purchase obligations for the purchase of goods and services are defined as agreements that are enforceable and legally binding and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. Our purchase orders are based upon our current inventory needs and are fulfilled by our suppliers within short time periods. We also enter into contracts for outsourced services; however, the obligations under these contracts are not significant and the contracts generally contain provisions allowing for cancellation without significant penalty.

Contractual obligations that are contingent upon future performance and growth of sales are not included in the table above. These contractual obligations are the additional earn-out payments for the assets of Infusion Dynamics, through fiscal 2011, and the assets of Road Safety, through fiscal 2013.

Hedging Activities

At times, we use forward contracts to reduce our exposure to foreign currency risk due to fluctuations in exchange rates underlying the value of forecasted sales to subsidiaries denominated in foreign currencies as well as intercompany accounts receivable denominated in foreign currencies.

As of July 3, 2011 we had two foreign currency forward contracts designated as cash flow hedges in the amount of approximately $5.4 million, serving as a hedge of our forecasted sales to our subsidiaries, all maturing in less than twelve months. The net settlement amount of these contracts on July 3, 2011 was an unrealized loss of approximately $345,000, which is included within “Accumulated other comprehensive income” on our condensed consolidated balance sheet. We had a net realized loss of approximately $223,000 from foreign currency forward contracts designated as cash flow hedges during the quarter ended July 3, 2011, which was included in earnings within “Product sales” in the condensed consolidated statement of income. We did not have any foreign currency forward contracts designated as cash flow hedges during the quarter ended July 4, 2010. Any gains or losses on the fair value of the derivative contracts would be largely offset by the losses and gains on the underlying transactions. These offsetting gains and losses are not reflected above.

We did not have any foreign currency forward contracts not designated as hedging instruments outstanding at July 3, 2011. We had a net realized loss of approximately $141,000 from foreign currency forward contracts that settled during the quarter ended July 3, 2011, which is included in earnings within “investment and other income (expense), net,” compared to a net realized gain of approximately $547,000 for the prior year’s quarter. Any gains or losses on the fair value of the derivative contract would be largely offset by the losses and gains on the underlying transactions. These offsetting gains and losses are not reflected above.

Legal and Regulatory Affairs

We received a warning letter from the FDA, dated April 22, 2011, addressing certain aspects of battery life claims on our AED Plus product. We have provided the FDA with additional data and action plans concerning battery life claims. The FDA has reviewed the material and has indicated that our response appears to be adequate, pending re-inspection at some point in the future to insure that all actions have been implemented. We have always complied with warning letters we have received in the past, and we intend to address this warning letter to the full satisfaction of the FDA.

We are, from time to time, involved in the normal course of our business in various legal proceedings, including intellectual property, contract, employment and product liability suits. Although we are unable to quantify the exact financial impact of any of these matters, we believe that none of the currently pending matters will have an outcome material to our financial condition or business.

Critical Accounting Estimates

Our management strives to report our financial results in a clear and understandable manner, even though in some cases accounting and disclosure rules are complex and require us to use technical terminology. We follow accounting principles generally accepted in the United States in preparing our consolidated financial statements. These principles require us to make certain estimates of matters that are inherently uncertain and to make difficult and subjective judgments that affect our financial position and results of operations. Our most critical accounting policies include revenue recognition, and our most critical accounting estimates include accounts receivable reserves, warranty reserves, inventory reserves, fair value measurements, the valuation of goodwill and other long-lived assets, income taxes and stock-based compensation. Management continually reviews its accounting policies, how they are applied and how they are reported and disclosed in our financial statements. Following is a summary of our more significant accounting policies, which include revenue recognition and those that require significant estimates and judgments and uncertainties, and potentially could result in materially different results under different assumptions and conditions, and how they are applied in preparation of the financial statements.

Revenue Recognition

Revenues from sales of cardiac resuscitation and temperature management therapy devices, disposable electrodes, catheters and accessories are recognized when a signed non-cancelable purchase order exists, the product is shipped, title and risk have passed to the customer, the fee is fixed or determinable, and collection is considered probable. Circumstances that generally preclude the immediate recognition of revenue include shipping terms of FOB destination or the existence of a customer acceptance clause in a contract based

upon customer inspection of the product. In these instances, revenue is deferred until adequate documentation is obtained to ensure that these criteria have been fulfilled. Similarly, revenues from the sales of our products to distributors fall under the same guidelines. For all significant orders placed by our distributors, we require an approved purchase order, we perform a credit review, and we ensure that the terms on the purchase order or contract are proper and do not include any contingencies which preclude revenue recognition. We do not typically offer any special right of return, stock rotation or price protection to our distributors or end customers. For sales in which payment extends beyond a twelve month period, we generally recognize revenue at its net present value using an imputed rate of interest based on our experience of successful collection on these terms without concession.

Our sales to customers often include a device, disposables and other accessories. For the vast majority of our shipments, all deliverables are shipped together. However, in cases some elements of a multiple element arrangement are not delivered as of a reporting date. In September 2009, the FASB amended the accounting standards related to revenue recognition for arrangements with multiple deliverables and include some software elements. We adopted this new guidance prospectively during the first quarter of 2010. Under the historical accounting guidance, FASB ASC 605-25, Multiple Element Arrangements (formerly Emerging Issues Task Force (“EITF”) Issue No. 00-21, Accounting for Revenue Arrangements with Multiple Deliverables), we deferred the fair value of the undelivered elements and only recognized the revenue related to the delivered elements if we had established fair value for the undelivered elements. If we had not established fair value for any undelivered elements, the entire order was deferred. Under the new guidance of ASU No. 2009-13, Multiple-Deliverable Revenue Arrangements, fair value as the measurement criteria is replaced with the term selling price and establishes a hierarchy for determining the selling price of a deliverable. ASU No. 2009-13 also eliminates the use of the residual value method for determining the allocation of arrangement consideration. For multi-element arrangements, we allocate revenue to all deliverables based on their relative selling prices. In such circumstances, we use a hierarchy to determine the selling price to be used for allocating revenue to deliverables as follows: (i) vendor-specific objective evidence of fair value (“VSOE”), (ii) third-party evidence of selling price (“TPE”), and (iii) best estimate of the selling price (“ESP”). VSOE generally exists only when we sell the deliverable separately and is the price actually charged for that deliverable. Our process for determining an ESP for deliverables without VSOE or TPE considers multiple factors that may vary depending upon the unique facts and circumstances related to each deliverable. Revenues are recorded net of estimated returns.

We license software under non-cancelable license agreements and provide services including training, installation, consulting and maintenance, which consists of product support services, and unspecified upgrade rights (collectively, post-contract customer support, “PCS”). Revenue from the sale of software is recognized in accordance with FASB ASC 985-605, Software—Revenue Recognition (formerly SOP 97-2). License fee revenues are recognized when a non-cancelable license agreement has been signed, the software product has been delivered, there are no uncertainties surrounding product acceptance, the fees are fixed or determinable, and collection is considered probable. Revenues from maintenance agreements and upgrade rights are recognized ratably over the period of service. Revenue for services, such as software deployment and consulting, is recognized when the service is performed. Our software arrangements contain multiple elements, which include software products, services and PCS. Generally, we do not sell computer hardware products with our software products. We will occasionally facilitate the hardware purchase by providing information to the customer such as where to purchase the equipment. We generally do not have vendor-specific objective evidence of fair value for our software products. We do, however, have vendor-specific objective evidence of fair value for items such as consulting and technical services, deployment and PCS based upon the price charged when such items are sold separately. Accordingly, for transactions where vendor-specific objective evidence exists for undelivered elements but not for delivered elements, we use the residual method. Under the residual method, the total fair value of the undelivered elements, as indicated by vendor-specific objective evidence, is deferred and the difference between the total arrangement fee and the amount deferred for the undelivered elements is recognized as revenue related to the delivered elements. If we cannot objectively determine the fair value of any undelivered element included in such multiple-element arrangements, we defer revenue until all elements are delivered and services have been performed, or until fair value can objectively be determined for any remaining undelivered elements.

We do not typically ship any of our software products to distributors or resellers. Our software products are sold by our sales force directly to the end user. We may sell software to system integrators who provide complete solutions to end users on a contract basis.

On September 28, 2009, we entered into a “state of readiness” contract awarded by the U.S. government to supply defibrillators on short notice. A similar contract with the U.S. government expired on September 27, 2009. Based upon the award, we expect to receive two types of payments from the U.S. government. The first payment of approximately $4 million, which was received during the first half of fiscal 2010 and is carried within “Deferred revenue” on our balance sheet as a liability under government contracts, is to reimburse us for the cost to acquire inventories required to meet potentially short-notice delivery schedules. We also expect to receive a payment from the U.S. government to compensate us for managing the purchase, build, storage and inventory rotation process. We expect that this payment will also compensate us for making future production capacity available. The portion of this payment associated with the purchase and build aspects of the contract we expect will be recognized on a proportional performance basis. The contract has a one-year term with up to an additional four one-year extensions. Under this contract, the U.S. Government has two options to acquire defibrillators. The U.S. Government may buy on a replenishment basis, which means we will record a sale under our normal U.S. Government price list and maintain our “state of readiness”, or the U.S. Government may buy on a non-replenishment basis, which will generally allow us to obtain normal margins but will reduce our future obligations under this arrangement.

For those markets for which we sell separately priced extended warranties, revenue is deferred and recognized over the applicable warranty period, based upon the estimated selling price of such extended warranties.

We also generate rental revenue from our LifeVest product. Doctors prescribe the LifeVest equipment for use by their patients. The patients then rent the LifeVest product from us for use over a prescribed period of time, typically between two to three months. The patients are generally covered by health plan contracts, which typically contract with a third party payor that agrees to pay based on fixed or allowable reimbursement rates. Third-party payors are entities such as insurance companies, governmental agencies, health maintenance organizations or other managed-care providers. The rental income is recognized ratably over the rental period.

Allowance for Doubtful Accounts / Sales Returns and Allowances / Trade-In Allowances

We maintain an allowance for doubtful accounts for estimated losses, for which related provisions are included in bad-debt expense, resulting from the inability of our customers to make required payments. Specifically identified reserves are charged to selling and marketing expenses. Provisions for general reserves are charged to general and administrative expenses. We determine the adequacy of this allowance by regularly reviewing the aging of our accounts receivable and evaluating individual customer receivables, considering customers’ financial condition, historical experience, communications with the customers, credit history and current economic conditions. We also maintain an estimated reserve for potential future product returns and discounts given related to trade-ins and to current period product sales, which is recorded as a reduction of revenue. We analyze the rate of historical returns when evaluating the adequacy of the allowance for sales returns, which is included in the accounts receivable allowance amounts on our balance sheet.

As of July 3, 2011, our accounts receivable balance of $104.1 million is reported net of allowances of $8.2 million. We believe our reported allowances at July 3, 2011 are adequate. If the financial conditions of our customers were to deteriorate, however, resulting in their inability to make payments, we might need to record additional allowances, resulting in additional expenses being recorded for the period in which such determination would be made.

Although we are not typically contractually obligated to provide trade-in allowances under existing sales contracts, we may offer such allowances when negotiating new sales arrangements. When pricing sales transactions, we contemplate both cash consideration and the net realizable value of any used equipment to be traded in. The trade-in allowance value stated in a sales order may differ from the estimated net realizable value of the underlying equipment. Any excess in the trade-in allowance over the estimated net realizable value of the used equipment represents additional sales discount.

We account for product sales transactions by recording as revenue the total of the cash consideration and the estimated net realizable value of the trade-in equipment less a normal profit margin. Any difference between the estimated net realizable value of the used equipment and the trade-in allowance granted is recorded as a reduction to revenue at the time of the sale.

Used ZOLL equipment is recorded at the lower of cost or market. We regularly review our reserves to ensure that the balance sheet value associated with our trade-in equipment is fairly stated.

If the trade-in equipment is a competitor’s product, we will usually resell the product to a third-party distributor who specializes in the sale of used medical equipment, without any refurbishment. We typically do not recognize a profit upon the resale of a competitor’s used equipment, although as a result of the inherent nature of the estimation process, we could recognize either a nominal gain or loss.

Warranty Reserves

Our products are sold with warranty provisions that require us to remedy deficiencies in quality or performance over a specified period of time, usually one year for pre-hospital and international customers and five years for hospital customers. Revenue is deferred for pre-hospital customers who receive warranties beyond one year. Such revenue is then recognized over the period of extended warranty. We provide for the estimated cost of product warranties at the time product is shipped and revenue is recognized. The costs that we estimate include material, labor, and shipping. While we engage in product quality programs and processes, our warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. We believe that our recorded liability of $4.4 million at July 3, 2011 is adequate to cover future costs for the servicing of our products sold through that date and under warranty. If actual product failure rates, material usage or service delivery costs differ from our estimates, revisions to the estimated warranty liability would be required.

Inventory

We value our inventories at the lower of cost or market. Cost is determined by the first-in, first-out (“FIFO”) method, including material, labor and factory overhead.

Inventory on hand may exceed future demand either because the product is outdated or obsolete, or because the amount on hand is in excess of future needs. We provide for the total value of inventories that we determine to be obsolete based on criteria such as customer demand and changing technologies. We estimate excess inventory amounts by reviewing quantities on hand and comparing those quantities to sales forecasts for the next 12 months, identifying historical service usage trends, and matching that usage with the installed base quantities to estimate future needs. At July 3, 2011, our inventory was recorded at net realizable value requiring reserves of $7.1 million, or 10% of our $72.9 million gross inventories. At October 3, 2010, the Company’s inventory was recorded at net realizable value requiring reserves of $7.1 million, or 9.2% of the $77.0 million gross inventories.

Fair Value Measurements

During the first quarter of fiscal 2009, we adopted FASB ASC 820, Fair Value Measurements and Disclosures (formerly referenced as SFAS No. 157, Fair Value Measurements), which defines fair value, establishes guidelines for measuring fair value and expands disclosures regarding fair value measurements. This accounting standard does not require any new fair value measurements. We apply fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. We elected to defer implementation of FASB ASC 820 as it relates to our non-financial assets and non-financial liabilities that are recognized and disclosed at fair value in the financial statements on a nonrecurring basis until fiscal 2010. The implementation of FASB ASC 820 as it relates to non-financial assets and non-financial liabilities that are recognized and disclosed at fair value in the financial statements on a nonrecurring basis did not have a material impact on our financial statements. We define fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions and credit risk.

During the first quarter of 2009, we adopted FASB ASC 825, Financial Instruments (formerly referenced as SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities—an amendment of FASB Statement No. 115), which allows companies to choose to measure eligible financial instruments and certain other items at fair value that are not required to be measured at fair value. We have not elected the fair value option for any eligible financial instruments.

Refer to Note 13, “Fair Value Measurements,” to the condensed consolidated financial statements in this Form 10-Q for additional information.

Goodwill

At July 3, 2011, we had approximately $79 million in goodwill, primarily resulting from our acquisitions of the assets of Lifecor Corporation (approximately $45 million), Revivant, Inc. (approximately $22 million), certain assets of BIO-key International, Inc. (approximately $5 million), the assets of Infusion Dynamics, Inc. (approximately $4 million), and the assets of Alsius Corporation (approximately $3 million). We test our goodwill for impairment annually at the end of our fiscal fourth quarter by comparing the fair value of our reporting units to the carrying value of those reporting units. Additionally, we periodically review our goodwill for impairment whenever events or changes in circumstances indicate that a potential impairment has occurred.

For our 2010 fiscal year-end annual impairment assessment, we identified four reporting units which have goodwill allocated to them and are ultimately aggregated up to our single reportable segment. Fair value is determined based on the income approach, which is an estimate of the discounted future cash flows expected from the reporting units. We considered the use of the market approach and the cost approach, but we concluded that these methods were not appropriate for valuing our reporting units due to the lack of relevant and available market comparisons. The income approach is based on the projected cash flows that are discounted to their present value using discount rates that consider the timing and risk of the forecasted cash flows. We believe that this approach is appropriate because it provides a fair value estimate based upon the reporting units’ expected long-term operating cash performance. The key variables that drive the fair value of our reporting units are estimated revenue growth rates, expense levels and discount rate assumptions. The projected cash flows use internally-developed revenue and expense forecasts and assumptions. The discount rate used is the average estimated value of a market participant’s cost of capital and debt, derived using customary market metrics. Other significant assumptions include terminal value margin rates, future capital expenditures and changes in future working capital requirements. We also compare our overall fair value to our market capitalization. While there are inherent uncertainties related to the assumptions used and to our application of these assumptions to this analysis, we believe that the income approach provides a reasonable estimate of the fair value of our reporting units. The foregoing assumptions were consistent with our long-term performance. However, these assumptions could deviate materially from actual results.

Our 2010 annual goodwill impairment testing did not identify any reporting units whose carrying values exceeded implied fair values. We believe that none of our reporting units has a material amount of goodwill that is at risk of failing future impairment tests. For each of the reporting units, the level of excess fair value over the carrying value exceeded 25% at the end of our 2010 fiscal year. The determination of fair value requires significant judgment on the part of management about future revenues, expenses and other assumptions that contribute to the net cash flows of the reporting units. Although we use consistent methodologies in developing the assumptions and estimates underlying the fair value calculations used in impairment tests, these estimates are uncertain by nature and can vary from actual results.

As of July 3, 2011, no events occurred or circumstances changed that might indicate that the fair value of any of our reporting units with goodwill is less than its book value.

Long-Lived Assets

We periodically review the carrying amount of our long-lived assets, including property and equipment, and intangible assets, to assess potential impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. The determination includes evaluation of factors such as current market value, business climate and future cash flows expected to result from the use of the related assets. Fair value is determined based on an estimate of the undiscounted cash flows in assessing potential impairment and to record an impairment loss based on fair value in the period when it is determined that the carrying amount of the asset may not be recoverable. This process requires judgment on the part of management.

Income Taxes

We use the asset and liability method of accounting for deferred income taxes. The provision for income taxes includes income taxes currently payable and those deferred as a result of temporary differences between the financial statement and tax bases of assets and liabilities. A valuation allowance is provided to reduce deferred tax assets to the amount of future tax benefit when it is more likely than not that some portion of the deferred tax assets will not be realized. Projected future taxable income and ongoing tax planning strategies are considered and evaluated when assessing the need for a valuation allowance. Any increase or decrease in a valuation allowance could have a material adverse or beneficial impact on our income tax provision and net income in the period in which the determination is made.

We adopted the provisions of FASB ASC 740, Income Tax, formerly FASB Interpretation No. 48, “Accounting for Uncertainty in Income Taxes”, on October 1, 2007. The provision contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon audit, including resolutions of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. We reevaluate these uncertain tax positions on a quarterly basis. This evaluation is based on factors including, but not limited to, changes in facts or circumstances, changes in tax law, effectively settled issues under audit and new audit activity. Any change in these factors could result in the recognition of a tax benefit or an additional charge to the tax provision. This provision also provides guidance on classification, interest and penalties, accounting in interim periods, disclosure and transition.

Stock-Based Compensation

In accordance with FASB ASC Topic 718, Compensation—Stock Compensation, we measure the cost of employee services in exchange for an award of equity instruments based on the grant-date fair value of the award and recognize cost over the requisite service period. We recognize compensation expense on fixed awards with pro rata vesting on a straight-line basis over the vesting period.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

We have cash equivalents and marketable securities that primarily consist of money market accounts and fixed-rate, asset-backed corporate securities. The majority of these investments have maturities within one to five years. We believe that our exposure to interest rate risk is minimal due to the term and type of our investments and that the fluctuations in interest rates would not have a material adverse effect on our results of operations.

We have international subsidiaries in Canada, the United Kingdom, the Netherlands, France, Germany, Austria, Australia, New Zealand and China. These subsidiaries transact business in their functional or local currency. Therefore, we are exposed to foreign currency exchange risks and fluctuations in foreign currencies, along with economic and political instability in the foreign countries in which we operate, all of which could adversely impact our results of operations and financial condition.

At times, we use foreign currency forward contracts to manage our currency transaction exposures from forecasted foreign currency denominated sales to our subsidiaries. These foreign currency forward contracts are designated as cash flow hedges under FASB ASC 815, Derivatives and Hedging. Therefore the effective portion of the gain or loss is reported as a component of other comprehensive income and will be reclassified into earnings in the same period or periods during which the hedged forecasted transaction affects earnings. The ineffective portion of the derivative’s change in fair value is recognized currently through earnings regardless of whether the instrument is designated as a hedge. At July 3, 2011, we had two foreign currency forward contracts outstanding designated as hedging instruments, all maturing in less than twelve months, to exchange the Euro for U.S. Dollars totaling approximately $5.4 million. A sensitivity analysis of a change in the fair value of the derivative foreign exchange contracts outstanding at July 3, 2011 indicates that, if the U.S. dollar weakened by 10% against the different foreign currencies, the fair value of these contracts would decrease by approximately $581,000 resulting in a total loss on the contracts of approximately $926,000. Conversely, if the U.S. dollar strengthened by 10% against the different foreign currencies, the fair value of these contracts would increase by approximately $528,000 resulting in a total gain on the contracts of approximately $183,000. Any gains and losses on the fair value of the derivative contracts would be largely offset by losses and gains on the underlying transactions. These offsetting gains and losses are not reflected in the analysis below.

We also at times use foreign currency forward contracts not designated as hedging instruments to manage our currency transaction exposures. These derivative instruments are marked-to-market with changes in fair value recorded to earnings. These derivative instruments do not subject our earnings or cash flows to material risk since gains and losses on those derivatives generally offset losses and gains on the assets and liabilities being hedged. We did not have any foreign currency forward contracts not designated as hedging instruments outstanding at July 3, 2011.

Cash Flow Hedges

Exchange Rate Sensitivity: July 3, 2011

(Amounts in $)


	Expected Maturity Dates												Total		Unrealized loss
	2011		2012		2013		2014		2015		Thereafter		Total		Unrealized loss
Forward Exchange Agreements (Receive $/Pay Euro) Contract Amount	$	5,433,000											$	5,433,000	$	345,000
Average Contract Exchange Rate		1.3582		—		—		—		—		—		1.3582

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Based on an evaluation under the supervision and with the participation of the Company’s management, the Company’s principal executive officer and principal financial officer have concluded that the Company’s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), were effective as of July 3, 2011, to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms and (ii) accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosures.

Changes in Internal Controls Over Financial Reporting

There have been no changes in the Company’s internal controls over financial reporting that occurred during the quarter ended July 3, 2011 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

The Company is, from time to time, involved in the normal course of its business in various legal proceedings, including intellectual property, contract, employment and product liability suits. Although we are unable to quantify the exact financial impact of any of these matters, we believe that none of the currently pending matters will have an outcome material to our financial condition or business.

Item 1A.

Risk Factors

There have been no material changes to the Risk Factors previously disclosed in Part I, Item 1A, “Risk Factors,” in our Annual Report on Form 10-K for the year ended October 3, 2010, which was filed with the SEC on December 17, 2010, except that we have modified the following risk factors:

If We Fail to Comply With Applicable Regulatory Laws and Regulations, the FDA and Other U.S. and Foreign Regulatory Agencies Could Exercise Any of Their Regulatory Powers, Which Could Have a Material Adverse Effect on Our Business.

Every company that manufactures or assembles medical devices is required to register with the FDA and to adhere to certain quality systems, which regulate the manufacture of medical devices and prescribe record keeping procedures and provide for the routine inspection of facilities for compliance with such regulations. The FDA also has broad regulatory powers in the areas of clinical testing, marketing and advertising of medical devices. To ensure that manufacturers adhere to good manufacturing practices, medical device manufacturers are routinely subject to periodic inspections by the FDA. If the FDA believes that a company may not be operating in compliance with applicable laws and regulations, it could take any of the following actions:

•

place the company under observation and re-inspect the facilities;

•

issue a warning letter apprising of violating conduct;

•

detain or seize products;

•

mandate a recall;

•

enjoin future violations; and

•

assess civil and criminal penalties against the company, its officers or its employees.

We, like most of our U.S. competitors, have received warning letters from the FDA in the past, and we may receive warning letters in the future. The number of warning letters issued within the industry has been on the rise; for example, the number of warning letters issued within the industry in 2009 and 2010 significantly exceeded the number of warning letters issued prior to this period. We recently received a warning letter from the FDA, dated April 22, 2011, addressing certain aspects of battery life claims on our AED Plus product. We have provided additional data and action plans concerning battery life claims to the FDA. The FDA has reviewed the material and has indicated that our response appears to be adequate, pending re-inspection at some point in the future to insure that all actions have been implemented. We expect to fully comply with the actions required by this warning letter. However, our failure to comply with FDA regulations could result in sanctions being imposed on us, including restrictions on the marketing or recall of our products. These sanctions could have a material adverse effect on our business.

In general, the FDA is becoming increasingly active in its regulatory activities. For example, the FDA recently launched an initiative to facilitate the development of safer and more effective external defibrillators through improved design and manufacturing practices. The FDA states its initiative will promote innovation of next-generation external defibrillators, enhance the ability of the external defibrillator industry and the FDA to identify and respond to safety problems and risks more quickly and effectively, and designate an appropriate premarket regulatory pathway for AEDs that promotes best practices for design and testing. As a result of this initiative, we expect the FDA to focus greater scrutiny on external defibrillator companies such as ZOLL.

If a foreign regulatory agency believes that we are not operating in compliance with their laws and regulations, they could prevent us from selling our products in their country, which could have a material adverse effect on our business.

Our LifeVest Product is a Reimbursable Product and is Subject to Risks that are Different from Our Capital Equipment Business.

The LifeVest product is our first reimbursed product which is different than our typical capital equipment business. The LifeVest product is governed by the Durable Medical Equipment Regulations and is subject to audit. The LifeVest is reimbursed by Medicare, Medicaid or other third-party payors that may limit coverage or reduce reimbursement rates with little notice, which may have an adverse impact on sales of our LifeVest product.

On August 4, 2011, a Durable Medical Equipment Regional Carrier issued for comment draft revisions to the local coverage determinations with respect to Medicare reimbursement for automated external defibrillators and wearable defibrillators, including our LifeVest product. The draft revisions would limit the indications for Medicare reimbursement for the LifeVest product. These draft revisions are subject to public hearings and comments. We believe that following the public hearing process, the current indications for Medicare reimbursement of the LifeVest product will not be limited; however, in the event the draft revisions were to become final, the draft limitations on the indications for Medicare reimbursement would have a material adverse effect on our LifeVest business.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

The following table provides information for the quarter ended July 3, 2011 regarding shares of Common Stock transferred by employees to the Company to satisfy the tax withholding obligations of such employees in connection with the vesting of restricted Common Stock under the Company’s 2001 Plan.


Period	(a) Total Number of Shares Purchased		(b) Average Price Paid per Share		(c) Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	(d) Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plans or Programs
April 4, 2011 – May 3, 2011		2,802	$	47.45	N/A	N/A
May 4, 2011 – June 3, 2011		—	$	—	N/A	N/A
June 4, 2011 – July 3, 2011		—	$	—	N/A	N/A
Total		2,802	$	47.45	N/A	N/A

Item 5.

Other Information

None.

Item 6.

Exhibits


Exhibit No.		Exhibit

31.1		Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. (1)

31.2		Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. (1)

32.1*		Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (2)

32.2*		Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (2)

(1)	Filed herewith.

(2)	Furnished herewith.

This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.

**	XBRL Interactive Data File will be filed by amendment to this Form 10-Q within 30 days of the filing date of this Form 10-Q, as permitted by Rule 405(a)(2)(ii) of Regulation S-T.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	ZOLL MEDICAL CORPORATION

Date: August 8, 2011	By:	/s/ RICHARD A. PACKER
		Richard A. Packer,
		Chief Executive Officer
		(Principal Executive Officer)

EXHIBIT INDEX


Exhibit No.		Exhibit

31.1		Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. (1)

31.2		Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. (1)

32.1*		Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (2)

32.2*		Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (2)

(1)	Filed herewith.

(2)	Furnished herewith.

**	XBRL Interactive Data File will be filed by amendment to this Form 10-Q within 30 days of the filing date of this Form 10-Q, as permitted by Rule 405(a)(2)(ii) of Regulation S-T.

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if a smaller reporting company)

Smaller reporting company